PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1655330-0 1991 Plasma and tissue kallikrein-kinin systems during acute administration of frusemide in normotensive and hypertensive humans. Furosemide 74-83 kallikrein related peptidase 4 Homo sapiens 18-28 1655330-5 1991 Frusemide increased plasma pre-kallikrein, angiotensin II and aldosterone concentrations and plasma renin activity, whereas the plasma level of tissue kallikrein remained unchanged. Furosemide 0-9 kallikrein related peptidase 4 Homo sapiens 31-41 1655330-8 1991 Frusemide increased the urine volume and the excretion of Na+, K+, Mg2+, Cl-, aldosterone, prostaglandin E2 and tissue kallikrein. Furosemide 0-9 kallikrein related peptidase 4 Homo sapiens 119-129 1655330-12 1991 Thus, acute administration of frusemide to hypertensive patients and normal subjects increased the plasma level of pre-kallikrein, possibly indicating less activation to kallikrein and subsequently less kinin generation in the blood stream. Furosemide 30-39 kallikrein related peptidase 4 Homo sapiens 119-129 1655330-12 1991 Thus, acute administration of frusemide to hypertensive patients and normal subjects increased the plasma level of pre-kallikrein, possibly indicating less activation to kallikrein and subsequently less kinin generation in the blood stream. Furosemide 30-39 kallikrein related peptidase 4 Homo sapiens 170-180 1655330-16 1991 Urinary excretion of kallikrein is reduced in patients with primary hypertension after the administration of frusemide, apparently without affecting the renal excretory response. Furosemide 109-118 kallikrein related peptidase 4 Homo sapiens 21-31 3926510-10 1985 When compared with salt-insensitive patients, salt-sensitives had lower levels of urinary kallikrein excretion and a blunted kallikrein response to dietary sodium restriction and furosemide. Furosemide 179-189 kallikrein related peptidase 4 Homo sapiens 125-135 2087934-0 1990 Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients. Furosemide 82-92 kallikrein related peptidase 4 Homo sapiens 34-44 2087934-6 1990 Both PRA and kallikrein levels increased after furosemide in controls while in diabetics this response was severely blunted. Furosemide 47-57 kallikrein related peptidase 4 Homo sapiens 13-23 2167800-10 1990 After frusemide there was a small transient increase in excretion of active kallikrein 1-2 h after dosing which coincided with the maximum diuresis and natriuresis. Furosemide 6-15 kallikrein related peptidase 4 Homo sapiens 76-86 3324714-0 1987 Diminution by captopril of the diuretic, natriuretic and kallikrein stimulating action of furosemide by reduction in its renal secretion. Furosemide 90-100 kallikrein related peptidase 4 Homo sapiens 57-67 3324714-6 1987 After furosemide injection changes in plasma aldosterone concentration paralleled changes in renal kallikrein and kinin excretion. Furosemide 6-16 kallikrein related peptidase 4 Homo sapiens 99-109 3324714-7 1987 However, after captopril there was a sharp dissociation between aldosterone, which was diminished by captopril continuously, and renal kallikrein and kinins, which were still stimulated by furosemide. Furosemide 189-199 kallikrein related peptidase 4 Homo sapiens 135-145 3324714-8 1987 These results suggest that renal kallikrein-kinin system is stimulated by furosemide directly and independently of aldosterone secretion. Furosemide 74-84 kallikrein related peptidase 4 Homo sapiens 33-43 3549580-0 1987 Acute effect of furosemide on renal kallikrein and prostaglandin systems in mild to moderate essential hypertension. Furosemide 16-26 kallikrein related peptidase 4 Homo sapiens 36-46 1780509-5 1991 Urinary kallikrein in hypertense non-diabetic patients who are not treated with diuretics (furosemide) has a behaviour as in normal controls, but it is much higher in patients treated with captopril, being this finding of great importance since it can suggest new therapeutic approaches to diabetic nephropathy. Furosemide 91-101 kallikrein related peptidase 4 Homo sapiens 8-18 6111397-0 1981 [Renal excretion of kallikrein after water loading and administration of furosemide or the beta-adrenergic blocker, trimepranol. Furosemide 73-83 kallikrein related peptidase 4 Homo sapiens 20-30 6160345-0 1981 Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension. Furosemide 62-72 kallikrein related peptidase 4 Homo sapiens 15-25 6160345-2 1981 Furosemide therapy significantly reduced mean arterial pressure (108.6 +/- 2.4 vs. 101.0 +/- 2.7 mm Hg, p < 0.02) in association with a significant increase in 24 hr urinary kallikrein activity (7.9 +/- 1.8 vs. 13.4 +/- 2.8 esterase units/24 hr, p < 0.02). Furosemide 0-10 kallikrein related peptidase 4 Homo sapiens 177-187 6160345-4 1981 A significant (p < 0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide. Furosemide 205-215 kallikrein related peptidase 4 Homo sapiens 91-101 6160345-4 1981 A significant (p < 0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide. Furosemide 205-215 kallikrein related peptidase 4 Homo sapiens 144-154 396074-4 1979 Frusemide increased urinary kallikrein excretion in normotensive subjects and in patients with essential hypertension. Furosemide 0-9 kallikrein related peptidase 4 Homo sapiens 28-38 396074-5 1979 The stimulating effect of frusemide on urinary kallikrein was significantly diminished in patients with essential hypertension. Furosemide 26-35 kallikrein related peptidase 4 Homo sapiens 47-57